Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.93 and traded as high as $2.42. Microbot Medical shares last traded at $2.36, with a volume of 967,058 shares.
Analyst Upgrades and Downgrades
MBOT has been the topic of several analyst reports. Wall Street Zen upgraded Microbot Medical from a "sell" rating to a "hold" rating in a research report on Saturday, June 14th. HC Wainwright reaffirmed a "buy" rating and set a $9.00 price objective on shares of Microbot Medical in a research report on Thursday, April 10th.
Check Out Our Latest Analysis on Microbot Medical
Microbot Medical Stock Up 0.4%
The firm has a market cap of $90.95 million, a PE ratio of -3.85 and a beta of 1.14. The firm's fifty day simple moving average is $2.53 and its two-hundred day simple moving average is $1.95.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 21st. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.07. As a group, analysts anticipate that Microbot Medical Inc. will post -0.71 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Microbot Medical
Several large investors have recently made changes to their positions in MBOT. Geode Capital Management LLC boosted its stake in shares of Microbot Medical by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock worth $160,000 after acquiring an additional 10,442 shares during the period. Virtu Financial LLC bought a new position in Microbot Medical in the 1st quarter worth approximately $42,000. Goldman Sachs Group Inc. bought a new position in Microbot Medical in the 1st quarter worth approximately $57,000. Finally, Renaissance Technologies LLC purchased a new stake in Microbot Medical during the 4th quarter valued at approximately $118,000. 16.30% of the stock is currently owned by hedge funds and other institutional investors.
About Microbot Medical
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
See Also
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
